China Still Alluring? AZ, Pfizer Feel COVID Pinch, New Pricing Scheme Clouds Outlook

Pandemic Impact Starts Surfacing

 
• By Brian Yang

Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.

China growth
LEADING MNCS IN CHINA FEEL PINCH FROM COVID-19 AND NEW VBP CLOUDS FORECAST • Source: Shutterstock

More from Business

More from Scrip